Package Leaflet: Information for the User
Rivaroxaban Sun 2.5 mg film-coated tablets EFG
Read the entire package leaflet carefully before starting to take this medication, as it contains important information for you.
Contents of the Package Leaflet
You have been prescribed rivaroxaban because
Rivaroxaban reduces the risk of having another myocardial infarction in adults, or reduces the risk of death due to heart or blood vessel disease.
You will be prescribed rivaroxaban along with another medication. Your doctor will also instruct you to take:
or
Rivaroxaban reduces the risk of blood clot formation (atherothrombotic events) in adults.
You will be prescribed rivaroxaban along with another medication. Your doctor will also instruct you to take aspirin.
In some cases, if you are given rivaroxaban after an intervention to open a narrowed or closed artery in your leg to restore blood flow, your doctor may also prescribe clopidogrel for you to take in addition to aspirin for a short period of time.
Rivaroxaban Sun contains the active ingredient rivaroxaban, which belongs to a group of medications called antithrombotic agents. It works by blocking a clotting factor (factor Xa) and thus reducing the tendency of blood to form clots.
Do not take Rivaroxaban Sun
Do not take Rivaroxaban and inform your doctorif any of these circumstances apply to you.
Warnings and precautions
Consult your doctor or pharmacist before starting to take rivaroxaban.
Rivaroxaban should not be used in combination with other medications that reduce blood clotting, other than aspirin or clopidogrel/ticlopidine, such as prasugrel or ticagrelor.
Be careful with Rivaroxaban
Inform your doctor if you have any of these situationsbefore taking rivaroxaban. Your doctor will decide if you should be treated with this medication and if you should be kept under closer observation.
If you need surgery:
Children and adolescents
Rivaroxaban Sun 2.5 mg film-coated tablets are not recommended for children and adolescents under 18 years of age.There is not enough information about their use in children and adolescents.
Other medications and Rivaroxaban
Inform your doctor or pharmacist if you are using, have recently used, or may need to use any other medication, including those purchased without a prescription.
If any of these circumstances apply to you,inform your doctorbefore taking rivaroxaban, as the effect of rivaroxaban may be increased. Your doctor will decide if you should be treated with this medication and if you should be kept under closer observation.
If your doctor considers that you have a higher risk of developing a stomach or intestinal ulcer, they may recommend that you also use a preventive treatment.
If any of these circumstances apply to you,inform your doctorbefore taking rivaroxaban, as the effect of rivaroxaban may be reduced. Your doctor will decide if you should be treated with rivaroxaban and if you should be kept under closer observation.
Pregnancy and breastfeeding
Do not take rivaroxaban if you are pregnant or breastfeeding. If there is any possibility that you may become pregnant, use a reliable contraceptive while taking rivaroxaban. If you become pregnant while taking rivaroxaban, inform your doctor immediately, who will decide how you should be treated.
Driving and using machines
Rivaroxaban may cause dizziness (a common side effect) or fainting (an uncommon side effect) (see section 4, "Possible side effects"). You should not drive, ride a bicycle, or use tools or machines if you are affected by these symptoms.
Rivaroxaban Sun contains lactose and sodium
If your doctor has told you that you have an intolerance to certain sugars, consult them before taking rivaroxaban.
This medication contains less than 23 mg of sodium (1 mmol) per film-coated tablet; this is essentially "sodium-free".
Follow the instructions for administration of this medication exactly as indicated by your doctor. If you are unsure, consult your doctor or pharmacist again.
What dose to take
The recommended dose is one 2.5 mg tablet twice a day. Take rivaroxaban at the same time every day (e.g., one tablet in the morning and one in the evening). This medication can be taken with or without food.
If you have difficulty swallowing the tablet whole, consult your doctor about other ways to take rivaroxaban. The tablet can be crushed and mixed with water or apple sauce, immediately before taking it.
If necessary, your doctor may also administer the crushed rivaroxaban tablet through a gastric tube.
You will be prescribed rivaroxaban along with another medication. Your doctor will instruct you to take aspirin (also known as acetylsalicylic acid). If you receive rivaroxaban after an acute coronary syndrome, your doctor may also instruct you to take clopidogrel or ticlopidine.
If you are given rivaroxaban after an intervention to open a narrowed or closed artery in your leg to restore blood flow, your doctor may also prescribe clopidogrel for you to take in addition to aspirin for a short period of time.
Your doctor will instruct you on the dose to take (usually between 75 and 100 mg of aspirin per day, or a dose of 75 to 100 mg of aspirin plus a daily dose of 75 mg of clopidogrel or a standard daily dose of ticlopidine).
When to start treatment with Rivaroxaban Sun
Treatment with rivaroxaban should be started as soon as possible, once the acute coronary syndrome has been stabilized, i.e., from 24 hours after hospital admission and at the time when parenteral anticoagulant treatment (by injection) would be discontinued.
Your doctor will instruct you on when to start treatment with rivaroxaban if you have been diagnosed with coronary artery disease or peripheral arterial disease.
The doctor will decide how long you should continue taking the treatment.
If you take more Rivaroxaban Sun than you should
If you have taken more rivaroxaban than you should, inform your doctor immediately or call the Toxicology Information Service, phone: 91 562 04 20, indicating the medication and the amount taken.
Taking too much rivaroxaban increases the risk of bleeding.
If you forget to take Rivaroxaban Sun
Do not take more than one tablet in a single day to make up for a forgotten dose. If you forget to take a dose, take the next tablet at the usual time.
If you interrupt treatment with Rivaroxaban Sun
Take rivaroxaban regularly for the time indicated by your doctor.
Do not interrupt treatment with rivaroxaban without first consulting your doctor. If you stop taking this medication, you may increase your risk of having another myocardial infarction, a stroke, or dying from a heart or blood vessel disease.
If you have any other questions about the use of this medication, ask your doctor or pharmacist.
Like all medicines, this medicine can cause adverse effects, although not all people suffer from them.
Like other similar medicines (antithrombotics), rivaroxaban may cause bleeding that can put the patient's life at risk. Excessive bleeding can cause a sudden drop in blood pressure (shock). In some cases, the bleeding may not be evident.
Inform your doctor immediately if you experience any of the following symptoms
Your doctor will decide whether to keep you under closer observation or change your treatment.
The frequency of these adverse effects is very rare (up to 1 in 10,000 people).
Severe allergic reactions are very rare (anaphylactic reactions, including anaphylactic shock; may affect up to 1 in 10,000 people) and uncommon (angioedema and allergic edema; may affect up to 1 in 100 people).
General list of possible adverse effects:
Frequent(may affect up to 1 in 10 people):
Uncommon(may affect up to 1 in 100 people):
Rare(may affect up to 1 in 1,000 people):
Very Rare(may affect up to 1 in 10,000 people)
Frequency not known(frequency cannot be estimated from available data):
Reporting of adverse effects
If you experience any type of adverse effect, consult your doctor or pharmacist, even if it is a possible adverse effect that is not listed in this prospectus. You can also report it directly through the Spanish Pharmacovigilance System for Human Use Medicines www.notificaRAM.es. By reporting adverse effects, you can contribute to providing more information on the safety of this medicine.
Keep this medicine out of sight and reach of children.
Do not use this medicine after the expiration date that appears on the packaging and on each blister after "CAD" or "EXP". The expiration date is the last day of the month indicated.
This medicine does not require special storage conditions.
Crushed tablets
Crushed tablets are stable in water or apple puree for up to 4 hours.
Medicines should not be thrown away through wastewater or household waste. Deposit the packaging and medicines you no longer need in the SIGRE Point of the pharmacy. Ask your pharmacist how to dispose of the packaging and medicines you no longer need. This will help protect the environment.
Composition of Rivaroxaban Sun
Tablet core: microcrystalline cellulose (E460), hypromellose 2910 (E464), lactose monohydrate, low-substituted hydroxypropylcellulose (E463), sodium croscarmellose (E486), sodium lauryl sulfate (E487), magnesium stearate (E572).
Tablet film coating: hypromellose 2910 (E464), lactose monohydrate, macrogol 4000 (E1521), titanium dioxide (E171), yellow iron oxide (E172), black iron oxide (E172).
See section 2 "Rivaroxaban Sun contains lactose and sodium".
Appearance of the product and package contents
Rivaroxaban Sun 2.5 mg film-coated tablets are pale yellow, round, 6 mm in diameter, and have "?" engraved on one side and "2.5" on the other.
Rivaroxaban Sun 2.5 mg film-coated tablets are packaged in transparent PVC/PVDC/Al blisters, in aluminum foil, in boxes of 10, 20, 21, 28, 30, 56, 60, 98, 100, 196, and 200 tablets.
Not all pack sizes may be marketed.
Marketing authorization holder
Sun Pharmaceutical Industries Europe B.V.
Polarisavenue 87
2132JH Hoofddorp
Netherlands
Manufacturer
Sun Pharmaceutical Industries Europe B.V.
Polarisavenue 87
2132JH Hoofddorp
Netherlands
or
Terapia S.A.
Strada Fabricii Nr. 124,
Cluj-Napoca, Jud. Cluj,
400632, Romania
You can request more information about this medicine by contacting the local representative of the marketing authorization holder:
Sun Pharma Laboratorios, S.L. Rambla de Catalunya 53-55 08007 Barcelona Spain Tel: +34-93-3427890 Date of last revision of the prospectus: November 2023 Detailed information about this medicine is available on the website of the Spanish Agency for Medicines and Health Products (AEMPS) http://www.aemps.gob.es/ |